Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients.

Schöning, Verena; Hammann, Felix (2022). Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients. Pharmaceutics, 14(9) MDPI 10.3390/pharmaceutics14091828

[img]
Preview
Text
pharmaceutics-14-01828-v3.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Drug interactions with other drugs are a well-known phenomenon. Similarly, however, pre-existing drug therapy can alter the course of diseases for which it has not been prescribed. We performed network analysis on drugs and their respective targets to investigate whether there are drugs or targets with protective effects in COVID-19, making them candidates for repurposing. These networks of drug-disease interactions (DDSIs) and target-disease interactions (TDSIs) revealed a greater share of patients with diabetes and cardiac co-morbidities in the non-severe cohort treated with dipeptidyl peptidase-4 (DPP4) inhibitors. A possible protective effect of DPP4 inhibitors is also plausible on pathophysiological grounds, and our results support repositioning efforts of DPP4 inhibitors against SARS-CoV-2. At target level, we observed that the target location might have an influence on disease progression. This could potentially be attributed to disruption of functional membrane micro-domains (lipid rafts), which in turn could decrease viral entry and thus disease severity.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine

UniBE Contributor:

Schöning, Verena and Hammann, Felix

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1999-4923

Publisher:

MDPI

Language:

English

Submitter:

Pubmed Import

Date Deposited:

27 Sep 2022 09:20

Last Modified:

28 Sep 2022 11:18

Publisher DOI:

10.3390/pharmaceutics14091828

PubMed ID:

36145576

Uncontrolled Keywords:

COVID-19 DPP4 inhibitors drug repurposing drug-disease interaction lipid rafts network analysis target-disease interaction

BORIS DOI:

10.48350/173230

URI:

https://boris.unibe.ch/id/eprint/173230

Actions (login required)

Edit item Edit item
Provide Feedback